SCHEMBL10104548

SCHEMBL10104548

Cc1cc(OC(F)(F)F)cc(C2=CCNCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.47
PRKD3 O94806 1/20 0.47
MARK3 P27448 1/20 0.47
PRKCI P41743 1/20 0.47
PRKCD Q05655 1/20 0.47
CAMK2B Q13554 1/20 0.47
CAMK2G Q13555 1/20 0.47
CAMK2D Q13557 1/20 0.47
BRSK1 Q8TDC3 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
MAP4K5 Q9Y4K4 1/20 0.47
HTR2C P28335 10/20 0.45
SIGMAR1 Q99720 2/20 0.41
QDPR P09417 3/20 0.40
TGFBR1 P36897 1/20 0.39
ACVR1 Q04771 1/20 0.39
KCNH2 Q12809 1/20 0.39
HTR7 P34969 3/20 0.38
HTR6 P50406 3/20 0.38
EHMT2 Q96KQ7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5319444 0.80 SIGMAR1 (0.57) HTR2CSIGMAR1QDPRTGFBR1ACVR1
SCHEMBL3392218 0.79 JAK2 (0.63) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL25864472 0.79 HTR2C (0.63) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL10104504 0.78 HTR2C (0.62) HTR2CSIGMAR1QDPRTGFBR1ACVR1
Hydrochloric Acid SCHEMBL5541194 0.78 JAK2 (0.65) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL2299855 0.77 JAK2 (0.56) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL15594899 0.71 HTR2C (0.53) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL19514110 0.69 JAK2 (0.50) JAK2PRKD3MARK3PRKCIPRKCD
SCHEMBL17232840 0.69 HTR2C (0.71) HTR2CSIGMAR1QDPR
SCHEMBL879205 0.69 GPR3 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 JAK2 200/4885PRKD3 685/4885MARK3 1465/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 JAK2 1170/4885PRKD3 1401/4885MARK3 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.